50 results on '"Halaban, Ruth"'
Search Results
2. Interferon-stimulated neutrophils as a predictor of immunotherapy response
3. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5
4. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
5. A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
6. Clonal determinants of organotropism and survival in metastatic uveal melanoma
7. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
8. Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
9. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
10. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma
11. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
12. CD4 T cells and toxicity from immune checkpoint blockade
13. Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade
14. Supplementary Figure 6 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
15. Supplementary Figure 4 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
16. Supplementary Tables 1-3 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
17. Supplementary Figure 3 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
18. Supplementary Figure 1 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
19. Supplementary Figure 2 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
20. Supplementary Figure 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
21. Supplementary Table 4 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
22. Data from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
23. Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
24. Supplementary Table 5 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
25. Data from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
26. Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
27. Supplementary Figure 5 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
28. Supplementary Table 6 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
29. Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
30. Supplementary Table Legends 1-6, Figure Legend 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
31. Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
32. Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
33. Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
34. Supplementary Figures S1-S5 from Plasma Markers for Identifying Patients with Metastatic Melanoma
35. Supplementary Materials and Methods from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
36. Supplementary Table 3 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
37. Supplementary Table S2 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
38. Data from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
39. Supplementary Table 1 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
40. Supplementary Figures S1-S6 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
41. Supplementary Table 2 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
42. Supplementary Table and Figure Legends from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
43. Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations
44. Unannotated Microprotein EMBOW Switches WDR5 Between Epigenetic and Mitotic Roles During the Cell Cycle
45. Integrative Molecular and Clinical Profiling of Acral Melanoma Identifies LZTR1 as a Key Tumor Promoter and Therapeutic Target
46. A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
47. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.
48. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
49. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.
50. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.